5245582026-07-012026-09-305245582026-09-305245582026-03-315245582026-04-012026-09-305245582026-07-012026-09-30in-capmkt:OtherExpenses1Member5245582026-07-012026-09-30in-capmkt:OtherExpenses2Member5245582026-04-012026-09-30in-capmkt:OtherExpenses1Member5245582026-04-012026-09-30in-capmkt:OtherExpenses2Member5245582026-09-30OtherNoncurrentFinancialAssetsDomain15245582026-09-30OtherNoncurrentAssetsDomain15245582026-09-30OtherNoncurrentAssetsDomain25245582026-09-30OtherNoncurrentAssetsDomain35245582026-09-30OtherNoncurrentAssetsDomain45245582026-09-30OtherCurrentFinancialAssetsDomain15245582026-09-30OtherCurrentFinancialAssetsDomain25245582026-09-30OtherCurrentAssetsDomain15245582026-09-30OtherCurrentAssetsDomain25245582026-09-30OtherCurrentAssetsDomain35245582026-09-30OtherCurrentAssetsDomain45245582026-09-30OtherCurrentFinancialLiabilitiesDomain15245582026-09-30OtherCurrentFinancialLiabilitiesDomain25245582026-09-30OtherCurrentFinancialLiabilitiesDomain35245582026-09-30OtherCurrentFinancialLiabilitiesDomain45245582026-09-30OtherCurrentFinancialLiabilitiesDomain55245582026-09-30OtherCurrentFinancialLiabilitiesDomain65245582026-09-30OtherCurrentLiabilitiesDomain15245582026-09-30OtherCurrentLiabilitiesDomain25245582026-09-30OtherCurrentLiabilitiesDomain35245582026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15245582026-07-012026-09-30RelatedPartyTransactionDomain15245582026-06-30RelatedPartyTransactionDomain15245582026-09-30RelatedPartyTransactionDomain15245582026-07-012026-09-30RelatedPartyTransactionDomain25245582026-06-30RelatedPartyTransactionDomain25245582026-09-30RelatedPartyTransactionDomain25245582026-07-012026-09-30RelatedPartyTransactionDomain35245582026-06-30RelatedPartyTransactionDomain35245582026-09-30RelatedPartyTransactionDomain35245582026-07-012026-09-30RelatedPartyTransactionDomain45245582026-06-30RelatedPartyTransactionDomain45245582026-09-30RelatedPartyTransactionDomain45245582026-07-012026-09-30RelatedPartyTransactionDomain55245582026-06-30RelatedPartyTransactionDomain55245582026-09-30RelatedPartyTransactionDomain55245582026-07-012026-09-30RelatedPartyTransactionDomain65245582026-06-30RelatedPartyTransactionDomain65245582026-09-30RelatedPartyTransactionDomain65245582026-07-012026-09-30RelatedPartyTransactionDomain75245582026-06-30RelatedPartyTransactionDomain75245582026-09-30RelatedPartyTransactionDomain75245582026-07-012026-09-30RelatedPartyTransactionDomain85245582026-06-30RelatedPartyTransactionDomain85245582026-09-30RelatedPartyTransactionDomain85245582026-07-012026-09-30RelatedPartyTransactionDomain95245582026-06-30RelatedPartyTransactionDomain95245582026-09-30RelatedPartyTransactionDomain95245582026-07-012026-09-30RelatedPartyTransactionDomain105245582026-06-30RelatedPartyTransactionDomain105245582026-09-30RelatedPartyTransactionDomain105245582026-07-012026-09-30RelatedPartyTransactionDomain115245582026-06-30RelatedPartyTransactionDomain115245582026-09-30RelatedPartyTransactionDomain115245582026-07-012026-09-30RelatedPartyTransactionDomain125245582026-06-30RelatedPartyTransactionDomain125245582026-09-30RelatedPartyTransactionDomain125245582026-07-012026-09-30RelatedPartyTransactionDomain135245582026-06-30RelatedPartyTransactionDomain135245582026-09-30RelatedPartyTransactionDomain135245582026-07-012026-09-30RelatedPartyTransactionDomain145245582026-06-30RelatedPartyTransactionDomain145245582026-09-30RelatedPartyTransactionDomain145245582026-07-012026-09-30RelatedPartyTransactionDomain155245582026-06-30RelatedPartyTransactionDomain155245582026-09-30RelatedPartyTransactionDomain155245582026-07-012026-09-30RelatedPartyTransactionDomain165245582026-06-30RelatedPartyTransactionDomain165245582026-09-30RelatedPartyTransactionDomain165245582026-07-012026-09-30RelatedPartyTransactionDomain175245582026-06-30RelatedPartyTransactionDomain175245582026-09-30RelatedPartyTransactionDomain175245582026-07-012026-09-30RelatedPartyTransactionDomain185245582026-06-30RelatedPartyTransactionDomain185245582026-09-30RelatedPartyTransactionDomain185245582026-07-012026-09-30RelatedPartyTransactionDomain195245582026-06-30RelatedPartyTransactionDomain195245582026-09-30RelatedPartyTransactionDomain195245582026-07-012026-09-30RelatedPartyTransactionDomain205245582026-06-30RelatedPartyTransactionDomain205245582026-09-30RelatedPartyTransactionDomain205245582026-07-012026-09-30RelatedPartyTransactionDomain215245582026-06-30RelatedPartyTransactionDomain215245582026-09-30RelatedPartyTransactionDomain215245582026-07-012026-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524558NEULANDLABNOTLISTEDINE794A01010NEULAND LABORATORIES LIMITEDMain BoardEquity2026-04-012027-03-312026-11-032026-10-22INRLakhsQuarterlySecond quarterSingle segmentManufacturing of Active Pharmaceuticals2026-11-0309:30:002026-11-0315:34:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-02-10https://cms.neulandlabs.com/sites/default/files/neuland-labs/Investors/corporate-governance/policies-and-documents/related-party-transactions-policy.pdffalsefalseNot Applicable2026-07-012026-09-30UnauditedStandalone449656900074934000457150300021578730000-64731500095052500073054000287685000106487400038866960006848070000684807000178679000-514700017353200005112750000000511275000-20630005092120001290050001039.8539.850039.8539.851. The financial results for the quarter and half year ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 03, 2026. The Statutory auditor have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2026. <br /> <br /> 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <br /> <br /> 3. The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments". In accordance with Ind AS 108 - 'Operating segments', segment information has been given in the unaudited consolidated financial results of the Company and therefore no separate disclosure on segment information is given in these unaudited standalone financial results. <br /> <br /> 4. The EPS for quarters has not been annualised. 2026-04-012026-09-30UnauditedStandalone109123400001598510001107219100044455650000-724769000198076800014277300055329400020143950008412026000266016500002660165000687482000-122110006752710000198489400000001984894000-2063000198283100012900500010154.71154.7100154.71154.71Manufacturing expenses578043000Other expenses486831000Manufacturing expenses1057400000Other expenses956995000994162500028429540000279461000038616000456400000214040000013726600015867000006155140001639655300055210020000294304000050670900039678280000145436000756301300007835400001386755500000302641080001290050002007612200020205127000202051270002963312000000296331200016161400066133000003786256000459760000145179000203436000021795390001125099000376439800023580890003093700011930100006272725000001005898100030264108000Security Deposits137266000Prepaid expenses1831000Capital advances589723000Balances with government authorities2337000Income tax assets (net)21623000Interest accrued on bank deposits101860000Unbilled revenues43576000Prepaid expenses210895000Advance to suppliers179346000Balances with government authorities314123000Export benefits receivable79176000Interest accrued but not due on borrowings397000Interest accrued on micro enterprises and small enterprises payable1212000Unclaimed dividends2173000Capital creditors209184000Employee benefits payable300302000Accrual for expenses611831000Advances from customers2266734000Liability towards Corporate Social Responsibility ('CSR') expenditure17968000Statutory liabilities73387000142773000-41813800024608840000-65664000-352000-19474000-316930000-5892340000-17285300005532940000149430000-371810000-3653900001598430000002354000003709000016681720004328337000000731449000035968880000000000022050002605834000000000000000000000896360000-1185038000-36990310000000000067940400022895300015556000436217000959520000-47012000-144286000-24642900057000-246372000753081000506709000Re-measurement gain/(loss) on defined benefit plans-2757000-2757000Re-measurement gain/(loss) on defined benefit plans-2757000-2757000-694000-694000-2063000-2063000Neuland Laboratories Limited******Dr. Davuluri Rama Mohan Rao******Executive Chairman and KMPRemunerationAs per the Companies Act, 2013 and Shareholders' Approval100751000-86700000-70751000Neuland Laboratories Limited******Mr. Davuluri Sucheth Rao******Executive Vice Chairman and KMPRemunerationAs per the Companies Act, 2013 and Shareholders' Approval100751000-78000000-70751000Neuland Laboratories Limited******Mr. Davuluri Saharsh Rao******CEO & Managing Director and KMPRemunerationAs per the Companies Act, 2013 and Shareholders' Approval100751000-78000000-70751000Neuland Laboratories Limited******Dr. Ravi Shankar Gopinath******Non-Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved240000-3500000-50000Neuland Laboratories Limited******Mr. Prasad Raghava Menon******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved370000-3500000-50000Neuland Laboratories Limited******Mr. Sugata Sircar******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved250000-3500000-50000Neuland Laboratories Limited******Ms. Pallavi Bhakru******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved350000-3500000-50000Neuland Laboratories Limited******Mr Homi Rustam Khusrokhan******Non Executive Independent DirectorAny other transactionSitting Fee & CommissionApproved330000-3500000-50000Neuland Laboratories Limited******Mr. Abhijit Majumdar******Chief Financial Officer and KMPRemunerationApproved11190000-3169000-2052000Neuland Laboratories Limited******Mrs. Sarada Bhamidipati******Company Secretary & Compliance OfficerRemunerationApproved3250000-442000-398000Neuland Laboratories Limited******Mrs. Davuluri Vijaya Rao******Relative of DirectorAny other transactionLease rentApproved499300000Neuland Laboratories Limited******Mr. Davuluri Sucheth Rao******Executive Vice Chairman and KMPAny other transactionOffice Lease rentApproved599300000Neuland Laboratories Limited******Mr. Davuluri Saharsh Rao******CEO & Managing Director and KMPAny other transactionOffice Lease rentApproved599300000Neuland Laboratories Limited******Mr. Davuluri Sucheth Rao******Executive Vice Chairman and KMPAny other transactionSecurity Deposit givenApproved01214000012140000Neuland Laboratories Limited******Mr. Davuluri Saharsh Rao******CEO & Managing Director and KMPAny other transactionSecurity Deposit givenApproved01214000012140000Neuland Laboratories Limited******Mrs. Davuluri Vijaya Rao******Relative of DirectorAny other transactionSecurity Deposit givenApproved019200001920000Neuland Laboratories Limited******Neuland Laboratories INC******Wholly owned subsidiaryAny other transactionBusiness PromotionApproved145467000-88222000-85620000Neuland Laboratories Limited******Neuland Laboratories KK******Wholly owned subsidiaryAny other transactionBusiness PromotionApproved17669000-7020000-7757000Neuland Laboratories Limited******Neuland Laboratories Limited Employees Group Gratuity Scheme******Post Employment Benefit TrustAny other transactionContribution to Employee Gratuity TrustApproved1800000000Neuland Laboratories Limited******Neuland Foundation******Entities with joint control or significant influence over entityAny other transactionContribution towards CSRApproved2008900000Neuland Laboratories Limited******Dr. Mauricio Futran******Non-Executive Non-Independent DirectorAny other transactionProfessional Fees, Sitting Fee & CommissionApproved200000050000536637000UnauditedtrueM S K A & Associates LLP, Chartered Accountantstrue2027-07-31